Ral J Andrade

List of Publications by Citations

176 papers	9,758 citations	47 h-index	95 g-index
210 ext. papers	11,791 ext. citations	5.5 avg, IF	5.96 L-index

#	Paper	IF	Citations
176	Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology*, **2005**, 129, 512-21	13.3	681
175	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*, **2005**, 128, 636-41	13.3	607
174	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. *Gastroenterology*, **2005**, 129, 512-521	13.3	554
173	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology*, **2011**, 141, 338-47	13.3	359
172	EASL Clinical Practice Guidelines: Drug-induced liver injury. *Journal of Hepatology*, **2019**, 70, 1222-1261	13.4	327
171	Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. *Gastroenterology*, **2006**, 131, 451-60	13.3	311
170	Drug-induced liver injury: recent advances in diagnosis and risk assessment. *Gut*, **2017**, 66, 1154-1164	19.2	250
169	Drug-induced liver injury: Interactions between drug properties and host factors. *Journal of Hepatology*, **2015**, 63, 503-14	13.4	231
168	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. *Hepatology*, **2006**, 44, 1581-8	11.2	223
167	Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. *Hepatology*, **2009**, 49, 2001-9	11.2	221
166	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. *Hepatology*, **2005**, 41, 779-89	11.2	214
165	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. *Hepatology*, **2011**, 54, 931-9	11.2	199
164	Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. *Gastroenterology*, **2014**, 147, 109-118.e5	13.3	186
163	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. *Gastroenterology*, **2019**, 156, 2230-2241.e11	13.3	184
162	Comparison of two clinical scales for causality assessment in hepatotoxicity. *Hepatology*, **2001**, 33, 123-30	11.2	181
161	Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. *Hepatology*, **2008**, 48, 588-96	11.2	162
160	Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. *Journal of Hepatology*, **2008**, 48, 721-7	13.4	158

159	Drug-induced liver injury. *Nature Reviews Disease Primers*, **2019**, 5, 58	51.1	148
158	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. *Gastroenterology*, **2017**, 152, 1078-1089	13.3	137
157	Causality assessment methods in drug induced liver injury: strengths and weaknesses. *Journal of Hepatology*, **2011**, 55, 683-691	13.4	130
156	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. *Hepatology*, **2006**, 44, 850-6	11.2	121
155	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. *Hepatology*, **2004**, 39, 1603-12	11.2	120
154	Hepatic safety of antibiotics used in primary care. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 1431-46	5.6	118
153	Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. *Hepatology*, **2019**, 69, 760-773	11.2	114
152	Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. *Drug Safety*, **2010**, 33, 503-22	5.1	110
151	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. *Hepatology*, **2009**, 50, 1702-8	11.2	110
150	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. *International Journal of Molecular Sciences*, **2016**, 17, 537	6.3	88
149	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. *Hepatology*, **2010**, 52, 303-12	11.2	85
148	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. *Journal of Hepatology*, **2016**, 65, 532-42	13.4	82
147	Drug-induced liver injury: insights from genetic studies. *Pharmacogenomics*, **2009**, 10, 1467-87	2.6	80
146	Trovafloxacin-induced acute hepatitis. *Clinical Infectious Diseases*, **2000**, 30, 400-1	11.6	77
145	Mechanisms of drug-induced liver injury. *Current Opinion in Allergy and Clinical Immunology*, **2014**, 14, 286-92	3.3	73
144	Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. *World Journal of Hepatology*, **2014**, 6, 160-8	3.4	69
143	Scientific opinion on the safety of green tea catechins. *EFSA Journal*, **2018**, 16, e05239	2.3	66
142	HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. *PLoS ONE*, **2013**, 8, e68111	3.7	66

141	Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. *Journal of Hepatology*, **2008**, 49, 107-14	13.4	63
140	Antidepressant-induced hepatotoxicity. *Expert Opinion on Drug Safety*, **2003**, 2, 249-62	4.1	63
139	Pharmacogenomics in drug induced liver injury. *Current Drug Metabolism*, **2009**, 10, 956-70	3.5	61
138	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. *Gastroenterology*, **2019**, 156, 1707-1716.e2	13.3	59
137	Causality assessment in drug-induced hepatotoxicity. *Expert Opinion on Drug Safety*, **2004**, 3, 329-44	4.1	59
136	Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. *European Journal of Clinical Pharmacology*, **2002**, 58, 435-40	2.8	58
135	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1495-1502	6.9	55
134	Assessment of drug-induced liver injury in clinical practice. *Fundamental and Clinical Pharmacology*, **2008**, 22, 141-58	3.1	54
133	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	54
132	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. *Gastroenterology*, **2018**, 155, 1120-1127.e4	13.3	47
131	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 216-225.e5	6.9	46
130	Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. *Journal of Hepatology*, **1999**, 31, 641-6	13.4	45
129	Biomarkers in DILI: One More Step Forward. *Frontiers in Pharmacology*, **2016**, 7, 267	5.6	43
128	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 31-41	18.8	43
127	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 1260-1270	6.1	43
126	Drug induced liver injury: an update. *Archives of Toxicology*, **2020**, 94, 3381-3407	5.8	40
125	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. *International Journal of Molecular Sciences*, **2016**, 17, 313	6.3	40
124	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. *Gastroenterology*, **2019**, 157, 552-568	13.3	39

123	Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. *Hepatology*, **2008**, 47, 810-6	11.2	39
122	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 817-28	5.5	38
121	Rechallenge in drug-induced liver injury: the attractive hazard. *Expert Opinion on Drug Safety*, **2009**, 8, 709-14	4.1	38
120	HLA-C and KIR genes in hepatitis C virus infection. *Human Immunology*, **2005**, 66, 1106-9	2.3	38
119	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. *European Journal of Gastroenterology and Hepatology*, **2002**, 14, 887-90	2.2	36
118	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 245-253	6.1	35
117	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 1028-1036	6.1	34
116	Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. *Liver International*, **2013**, 33, 1378-85	7.9	32
115	Metformin-induced hepatotoxicity. *Diabetes Care*, **2012**, 35, e21	14.6	32
114	The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. *Liver International*, **2015**, 35, 2474-82	7.9	31
113	Continuous reporting of new cases in Spain supports the relationship between Herbalife products and liver injury. *Pharmacoepidemiology and Drug Safety*, **2011**, 20, 1080-7	2.6	30
112	Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. *Liver International*, **2016**, 36, 302-10	7.9	29
111	Acute liver failure after treatment with nefazodone. *Digestive Diseases and Sciences*, **1999**, 44, 2577-9	4	27
110	Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. *Journal of Hepatology*, **1995**, 22, 189-96	13.4	27
109	The pro-/anti-inflammatory effects of different fatty acids on visceral adipocytes are partially mediated by GPR120. *European Journal of Nutrition*, **2017**, 56, 1743-1752	5.2	26
108	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. *Journal of Hepatology*, **2020**, 73, 17-25	13.4	26
107	Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. *Drug Safety*, **2014**, 37 Suppl 1, S19-31	5.1	26
106	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. *Annals of Hepatology*, **2014**, 13, 231-239	3.1	25

105	Hepatic Damage by Natural Remedies. *Seminars in Liver Disease*, **2018**, 38, 21-40	7.3	24
104	Fatal hepatitis associated with nimesulide. *Journal of Hepatology*, **2000**, 32, 174	13.4	24
103	Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. *Seminars in Liver Disease*, **2014**, 34, 145-61	7.3	23
102	Creating an effective clinical registry for rare diseases. *United European Gastroenterology Journal*, **2016**, 4, 333-8	5.3	22
101	Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. *Liver International*, **2017**, 37, 132-140	7.9	22
100	Benzylpenicillin-induced prolonged cholestasis. *Annals of Pharmacotherapy*, **2001**, 35, 783-4	2.9	22
99	Drug-induced liver injury: a safety review. *Expert Opinion on Drug Safety*, **2018**, 17, 795-804	4.1	21
98	Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity?. *Journal of Hepatology*, **2015**, 62, 751-2	13.4	21
97	Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. *Current Drug Safety*, **2010**, 5, 212-22	1.4	21
96	Drug use for non-hepatic associated conditions in patients with liver cirrhosis. *European Journal of Clinical Pharmacology*, **2003**, 59, 71-6	2.8	21
95	Genetic and molecular factors in drug-induced liver injury: a review. *Current Drug Safety*, **2007**, 2, 97-112	1.4	20
94	Drug-induced liver injury in older people. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 862-874	18.8	20
93	Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. *Drug Safety*, **2016**, 39, 925-43	5.1	19
92	Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. *Clinical Therapeutics*, **2009**, 31, 1014-9	3.5	19
91	Norfloxacin-induced cholestatic jaundice. *American Journal of Gastroenterology*, **1998**, 93, 2309-11	0.7	19
90	Hepatotoxicity induced by coxibs: how concerned should we be?. *Expert Opinion on Drug Safety*, **2016**, 15, 1463-1475	4.1	18
89	A morphological method for ammonia detection in liver. *PLoS ONE*, **2017**, 12, e0173914	3.7	18
88	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. *Journal of Hepatology*, **2021**, 75, 86-97	13.4	18

87	Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis. *AIDS Research and Human Retroviruses*, **2006**, 22, 1236-41	1.6	17
86	Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity?. *Annals of Pharmacotherapy*, **2004**, 38, 1540-1	2.9	17
85	Serum immunological profile in patients with chronic autoimmune cholestasis. *American Journal of Gastroenterology*, **2004**, 99, 2150-7	0.7	17
84	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. *Journal of Gastroenterology and Hepatology (Australia)*, **2016**, 31, 1611-8	4	17
83	Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. *Alimentary Pharmacology and Therapeutics*, **2000**, 14, 929-35	6.1	16
82	Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. *World Journal of Gastroenterology*, **2006**, 12, 5244-6	5.6	16
81	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. *Liver International*, **2020**, 40, 6-17	7.9	16
80	Chronic liver injury induced by drugs and toxins. *Journal of Digestive Diseases*, **2018**, 19, 514-521	3.3	16
79	Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. *PLoS ONE*, **2014**, 9, e94675	3.7	15
78	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles. *Pharmacogenetics and Genomics*, **2016**, 26, 414-22	1.9	15
77	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. *Seminars in Liver Disease*, **2019**, 39, 381-394	7.3	14
76	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). *Clinical Liver Disease*, **2019**, 13, 51-57	2.2	14
75	Systematic review: ibuprofen-induced liver injury. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 603-611	6.1	14
74	Sertraline hepatotoxicity: report of a case and review of the literature. *Digestive Diseases and Sciences*, **2010**, 55, 1806-7	4	14
73	Idiosyncratic drug hepatotoxicity: a 2008 update. *Expert Review of Clinical Pharmacology*, **2008**, 1, 261-76	3.8	14
72	The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. *European Journal of Gastroenterology and Hepatology*, **2005**, 17, 59-63	2.2	14
71	Chronic hepatitis C, ibuprofen, and liver damage. *American Journal of Gastroenterology*, **2002**, 97, 1854-5	0.7	14
70	"Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge". *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 589-93	5.5	13

69	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. *Journal of Hepatology*, **2018**, 68, 940-948	13.4	12
68	Drug-induced autoimmune-like hepatitis: a diagnostic challenge. *Digestive Diseases and Sciences*, **2011**, 56, 2501-2; author reply 2502-3	4	12
67	Severe idiosyncratic acute hepatic injury caused by paracetamol. *Journal of Hepatology*, **1998**, 28, 1078	13.4	12
66	Genetic Predisposition to Drug-Induced Liver Injury. *Clinics in Liver Disease*, **2020**, 24, 11-23	4.6	12
65	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1125-1135	6.1	12
64	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. *Annals of Hepatology*, **2014**, 13, 356-63	3.1	12
63	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. *United European Gastroenterology Journal*, **2019**, 7, 825-837	5.3	11
62	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. *PLoS ONE*, **2017**, 12, e0189436	3.7	11
61	Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. *Frontiers in Genetics*, **2012** , 3, 253	4.5	11
60	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. *Antioxidants*, **2021**, 10,	7.1	11
59	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 292-294	6.9	11
58	Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. *Frontiers in Pharmacology*, **2012**, 3, 2	5.6	10
57	Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. *Journal of Hepatology*, **2021**, 75, 935-959	13.4	10
56	Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid. *Digestive Diseases and Sciences*, **2001**, 46, 1416-9	4	9
55	A Revised Electronic Version of RUCAM for the Diagnosis of Drug Induced Liver Injury.. *Hepatology*, **2022**,	11.2	9
54	Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs?. *World Journal of Gastroenterology*, **2006**, 12, 5078-80	5.6	9
53	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. *Pharmacological Research*, **2021**, 164, 105404	10.2	9
52	The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. *Liver International*, **2019**, 39, 401-410	7.9	9

51	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. *Current Pharmaceutical Design*, **2019**, 25, 3855-3871	3.3	8
50	Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. *Revista Espanola De Enfermedades Digestivas*, **2012**, 104, 282-4	0.9	8
49	Genetic risk factors in the development of idiosyncratic drug-induced liver injury. *Expert Opinion on Drug Metabolism and Toxicology*, **2021**, 17, 153-169	5.5	8
48	Next-Generation Sequencing of Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. *Frontiers in Genetics*, **2019**, 10, 134	4.5	7
47	Acute leukemia after infliximab therapy. *American Journal of Gastroenterology*, **2003**, 98, 2577	0.7	7
46	Acute fulminant hepatitis after treatment with rabeprazole and terbinafine: is rabeprazole the culprit?. *Archives of Internal Medicine*, **2002**, 162, 360-1		7
45	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
44	Characterizing Drug-Induced Liver Injury With Autoimmune Features. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1844-1845	6.9	6
43	Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. *Phytotherapy Research*, **2021**, 35, 6-19	6.7	6
42	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. *Journal of Hepatology*, **2021**, 75, 333-341	13.4	6
41	Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. *Annals of Hepatology*, **2014**, 13, 231-9	3.1	6
40	Plasma ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients. *Journal of Clinical Gastroenterology*, **2012**, 46, 328-33	3	5
39	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. *Liver International*, **2021**, 41, 2076-2086	7.9	5
38	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1147-1158	6.1	5
37	Lansoprazole-induced hepatic dysfunction. *Annals of Pharmacotherapy*, **2003**, 37, 1731	2.9	4
36	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. *Drug Safety*,	5.1	4
35	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r □ dasabuvir □ ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. *PLoS ONE*, **2019**, 14, e0225061	3.7	3
34	Drug-induced liver and skin reactions: In need of a consensus definition. *Hepatology*, **2017**, 65, 391	11.2	3

33	Portal hypertension and refractory ascites associated with multicentric Castleman disease. *Digestive Diseases and Sciences*, **2000**, 45, 697-702	4	3
32	Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers. *Drug and Alcohol Dependence*, **1990**, 26, 161-8	4.9	3
31	Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.. *Acta Pharmaceutica Sinica B*, **2021**, 11, 3685-3726	15.5	3
30	Statins: Hepatic Disease and Hepatotoxicity Risk **2008**, 2, 18-23		3
29	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. *Liver International*, **2021**, 41, 1523-1531	7.9	3
28	Serious liver injury induced by Nimesulide: an international collaborative study. *Archives of Toxicology*, **2021**, 95, 1475-1487	5.8	3
27	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	3
26	Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury. *Journal of Pathology*, **2019**, 247, 110-122	9.4	3
25	Drug-Induced Liver Injury After Liver Transplantation. *Liver Transplantation*, **2020**, 26, 1167-1176	4.5	3
24	Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. *Antiviral Therapy*, **2006**, 11, 491-8	1.6	3
23	A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. *American Journal of Gastroenterology*, **2017**, 112, 384-385	0.7	2
22	Landscape of Liver Injury From Herbal and Dietary Supplements in Europe, Latin America, and Asia. *Clinical Liver Disease*, **2019**, 14, 49-50	2.2	2
21	Unusual duodenal duplication cyst associated with partial gastric diverticulum in a middle-aged woman: are they congenital or acquired?. *Digestive Diseases and Sciences*, **2002**, 47, 304-8	4	2
20	Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. *Drug Safety*, **2021**, 44, 619-634	5.1	2
19	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine‐learning approach. *Archives of Toxicology*, **2021**, 95, 1793-1803	5.8	2
18	Safety of treating acute liver injury and failure. *Expert Opinion on Drug Safety*, **2021**, 1-13	4.1	2
17	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. *Liver International*, **2021**, 41, 2671-2680	7.9	2
16	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. *Current Hepatology Reports*, **2017**, 16, 286-292	1	1

15	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. *Methods in Pharmacology and Toxicology*, **2018**, 477-496	1.1	1
14	Causality Assessment **2013**, 287-302		1
13	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.. *Journal of Hepatology*, **2022**,	13.4	1
12	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
11	Long-term sequelae of drug-induced liver injury. *Journal of Hepatology*, **2021**,	13.4	1
10	Drug-Induced Liver Disease: Mechanism and Diagnosis **2019**, 715-728		1
9	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 1604-1612	6.1	1
8	Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?. *Gastroenterology Report*, **2022**, 10, goac014	3.3	1
7	Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. *Antioxidants*, **2022**, 11, 897	7.1	1
6	Drug Induced Liver Disease: Mechanisms and Diagnosis **2010**, 771-786		0
5	Reply letter to "Editorial: bodybuilders beware". *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 473	6.1	
4	Reply: To PMID 24704526. *Gastroenterology*, **2015**, 148, 452-3	13.3	
3	Reply: To PMID 24704526. *Gastroenterology*, **2014**, 147, 1442	13.3	
2	Reply:. *Hepatology*, **2009**, 49, 1777-1779	11.2	
1	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. *Frontiers in Pharmacology*, **2016**, 7, 280	5.6	